febuxostat
Also known as Adenuric®, MX-67, Tei 6720, Tei-6720, TMX 67, Uloric®, Fébuxostat, Febuxostatum
Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels. It is generally recommended only for people who cannot take allopurinol. It is taken by mouth.
Research
1,660 papers- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.Lancet (London, England) · 2020
- Febuxostat compared with allopurinol in patients with hyperuricemia and gout.The New England journal of medicine · 2005
- Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.Arthritis & rheumatology (Hoboken, N.J.) · 2025
- Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials.Annals of medicine · 2024
- The role of febuxostat in gout.Current opinion in rheumatology · 2019
via PubMed
Article
11 sectionsContents
- Medical uses
- Side effects
- Drug interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Economics
- Brand names
- References
Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels. It is generally recommended only for people who cannot take allopurinol. It is taken by mouth.
Common side effects include liver problems, nausea, joint pain, and a rash. Serious side effects include an increased risk of death as compared with allopurinol, Stevens–Johnson syndrome, and anaphylaxis. Use is not recommended during pregnancy or breastfeeding. It inhibits xanthine oxidase, thus reducing production of uric acid in the body.